ASO Author Reflections: Prognostic Value of Subgrading G2 Pancreatic Neuroendocrine Tumors as 2A versus 2B-Reference-Cited by-同舟云学术

ASO Author Reflections: Prognostic Value of Subgrading G2 Pancreatic Neuroendocrine Tumors as 2A versus 2B

Published:2024-07-11 Issue: Volume: Page:
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Eren Ozgur Can,Bagci Pelin,Balci Serdar,Ohike Nobuyuki,Saka Burcu,Sokmensuer Cenk,Leblebici Can Berk,Xue Yue,Reid Michelle D.,Krasinskas Alyssa M.,Kooby David,Maithel Shishir K.,Sarmiento Juan,Cheng Jeanette D.,Taskin Orhun Cig,Kapran Yersu,Tarcan Zeynep,Luchini Claudio,Scarpa Aldo,Basturk Olca,Adsay N. Volkan

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1245/s10434-024-15728-5.pdf

Reference3 articles.

1. Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. BMC Cancer. 2023;23(1):908. https://doi.org/10.1186/s12885-023-11287-2.PMID:37752423;PMCID:PMC10523723.

2. Müller C, Kreissl MC, Klose S, Krause A, Keitel V, Venerito M. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. Medicine Balt. 2022;101(4):e28610. https://doi.org/10.1097/MD.0000000000028610.PMID:35089197;PMCID:PMC8797514.

3. Eren OC, Bagci P, Balci S, et al. Subgrading of G2 pancreatic neuroendocrine tumors as 2A (Ki67 3% to < 10%) versus 2B (10% to ≤ 20%) identifies behaviorally distinct subsets in keeping with the evolving management protocols. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15632-y.